1. Outcome after Radiofrequency Ablation of Sarcoma Lung Metastases
- Author
-
Sandra J. Strauss, Alice Gillams, and Claus Koelblinger
- Subjects
Adult ,Male ,medicine.medical_specialty ,Lung Neoplasms ,Adolescent ,Radio Waves ,Radiofrequency ablation ,medicine.medical_treatment ,law.invention ,law ,medicine ,Humans ,Radiology, Nuclear Medicine and imaging ,Child ,Survival rate ,Aged ,Retrospective Studies ,Chemotherapy ,Lung ,business.industry ,Soft tissue sarcoma ,Sarcoma ,Retrospective cohort study ,Middle Aged ,medicine.disease ,Primary tumor ,Surgery ,Survival Rate ,Treatment Outcome ,medicine.anatomical_structure ,Catheter Ablation ,Female ,Radiology ,Neoplasm Grading ,Tomography, X-Ray Computed ,Cardiology and Cardiovascular Medicine ,business - Abstract
Resection is the mainstay of management in patients with sarcoma lung metastases, but there is a limit to how many resections can be performed. Some patients with inoperable disease have small-volume lung metastases that are amenable to thermal ablation. We report our results after radiofrequency ablation (RFA). This is a retrospective study of patients treated from 2007 to 2012 in whom the intention was to treat all sites of disease and who had a minimum CT follow-up of 4 months. Treatment was performed under general anesthesia/conscious sedation using cool-tip RFA. Follow-up CT scans were analyzed for local control. Primary tumor type, location, grade, disease-free interval, prior resection/chemotherapy, number and size of lung tumors, uni- or bilateral disease, complications, and overall and progression-free survival were recorded. Twenty-two patients [15 women; median age 48 (range 10–78) years] with 55 lung metastases were treated in 30 sessions. Mean and median tumor size and initial number were 0.9 cm and 0.7 (range 0.5–2) cm, and 2.5 and 1 (1–7) respectively. Median CT and clinical follow-up were 12 (4–54) and 20 (8–63) months, respectively. Primary local control rate was 52 of 55 (95 %). There were 2 of 30 (6.6 %) Common Terminology Criteria grade 3 complications with no long-term sequelae. Mean (median not reached) and 2- and 3-year overall survival were 51 months, and 94 and 85 %. Median and 1- and 2-year progression-free survival were 12 months, and 53 and 23 %. Prior disease-free interval was the only significant factor to affect overall survival. RFA is a safe and effective treatment for patients with small-volume sarcoma metastases.
- Published
- 2013